Cybin's Deuterated Psychedelics Programs Protected By Three New International Patents

Cybin’s CYBN deuterated psychedelics programs received two patent grants from the United States Patent and Trademark Office (USPTO,) and one from the European Patent Office (EP.)

Headquartered in Canada and operational in-site as well as in the U.S., the U.K., the Netherlands and Ireland, the clinical-stage psychedelics biopharma company is building a centralized DMT-focused mental health therapies portfolio, consolidating its presence in the space with the recent acquisition of psychedelics biotech Small Pharma DMTTF.

Cybin’s goal of revolutionizing mental healthcare with safe and effective psychedelic-based therapies involves the development of CYB003, a novel deuterated psilocybin analog targeting Major Depressive Disorder (MDD;) and CYB004, a deuterated DMT molecule for Generalized Anxiety Disorder (GAD;) plus advancing a preclinical research pipeline.

Protections’ Extensions

The two U.S. patents on Cybin’s pipeline provide protection for the composition of matter for certain deuterated DMT analogs (no. 11,771,681), medical use and “novel, efficient and scalable synthesis” of certain DMT analogs (no. 11,773,062) until June 2040 and March 2041, respectively. 

Its European counterpart (EP no. 4,031,529) provides protection for the composition of matter and medical use for a list of deuterated tryptamine compounds including deuterated psilocybin analogs (CYB003 program) and deuterated DMT analogs (CYB004 program) until Nov. 2041.

The new combined company’s development programs are now protected by reportedly 33 granted patents and over 170 pending applications, in what would be “one of the most robust IP portfolios in the psychedelic drug development sector” says CEO Doug Drysdale. 

Cybin’s “multi-layered and robust” IP protection would enable it to potentially become a leader in developing novel tryptamine-based therapeutics in a “key” market with its deuterated programs.

“Maintaining a secure intellectual property position is fundamental to our development strategy as we continue to advance our novel molecules and optimize their therapeutic benefits,” Drysdale added.

Pipeline’s Status

Novel deuterated DMT compounds CYB004 and SPL028 are currently in Phase 1 clinical trials:

• Both molecules target an extended DMT-like psychedelic experience while retaining a short-duration drug profile toward optimizing dose formulations for different administration routes and several therapeutic benefits. 

• Preliminary study findings show that intravenous (IV) CYB004 and SPL028 elicit a psychedelic experience of less than 1 hour and are well-tolerated. 

• Topline data readouts are expected in 2023’s last quarter.

Meanwhile, the deuterated psilocybin analog CYB003 has completed dosing in a Phase 2 clinical trial in MDD: 

• Interim findings showed the molecule led to a “robust” psychedelic response in participants at low doses while maintaining a safe and well-tolerated therapeutic profile.

• Topline data readout is expected in 2023’s last quarter.

Photo: Benzinga edit with photo by Flametric, aiyoshi597, Gisele Yashar, Bacsica and Freedomz on Shutterstock.